

OPTIMUM'S 13TH ANNUAL HEALTHCARE INVESTOR CONFERENCE

4 October 2021

WELCOME TO THE 13TH OPTIMUM ANNUAL HEALTHCARE INVESTOR CONFERENCE

This will be the 13 year anniversary and we are delighted that the conference is now firmly established as a major thought leadership event in Europe.

This year we are going to be celebrating the numerous successes across our sector, the 'champions' who are making it happen and the investors who are investing in those champions.

One of the key positives arising from the coronavirus pandemic is that we have seen unprecedented collaborations across the industry which are revolutionising how the industry is working. Additionally, the money raised to finance biotech companies, early stage M&A, as well as the profile of the life sciences industry as a whole has reached tremendous highs and biopharma companies are finally being recognised more broadly for their innovation, adaptability and ability to get things done fast.

We are delighted to be able to deliver our conference, once more, in a virtual setting to bring together companies and investors far and wide to discuss and debate the issues and trends that will have a major impact on our industry far into the future.

We have two fantastic fireside chats for you today. Mike Ward, Head of Thought Leadership at Clarivate, in conversation with biotech investment guru, Francesco de Rubertis, Co-founder & Partner of Medicxi, on his career journey and his asset-centric approach to life sciences investing. Later in the afternoon Daniel Mahony, Co-Head of Healthcare at Polar Capital, talks to Rice Powell, Chief Executive Officer & Chairman of Fresenius Medical Care, the world's leading provider of products and services for people living with renal diseases, on putting patients first and how he sees the future of healthcare taking shape in the third decade of the 21st century.

Industry leaders will kick off our first panel of the day: 'Leaders of Successful European Biotech and Life Sciences Companies'.

Amber Tong, Senior Editor of Endpoints News, chairs our illustrious panel of CEO champions, celebrating the successes across our sector, and talking to the leaders who are making it happen!

Hannah Kuchler, Global Pharmaceuticals Correspondent at the Financial Times, chairs the public market investor panel 'Investing in Today's and Tomorrow's Innovative Companies'. This panel of leading investors will discuss the hot investment trends, the companies that are attracting attention and what we should be looking for in the future.

Stephen Hansen, Associate Editor at BioCentury, chairs the VC investor session which will focus on investing in early-stage companies and the success criteria for building future 'champions'. Panellists will discuss building world class teams, attracting the right level of finance and executing best strategies for success.

We are absolutely delighted to have such an illustrious group of panellists and speakers and I want to personally thank them for taking time out of their extremely busy schedules to speak at our event.

As always, we encourage questions and debate from you all, so please do participate via the online forums and social media using today's hashtag *#OptimumConnections*. We have an exceptional team of people at Optimum – all of whom will be available virtually in the chat rooms so please do reach out. We will also be producing a summary of these sessions in the coming months in our newsletter.

Thank you once again for being a part of our event – I hope that next year we will be able to see each other in person. Enjoy the afternoon.

Best wishes,

Mary Clark

Mary Clark, Managing Director, Optimum



AGENDA

All times UK

- 11:30am-12:30pm** **Registration & Networking Breakout Rooms Available**
- 12:30pm-12:40pm** **Welcome**
- Mary Clark, Managing Director, Optimum Strategic Communications
- 12:40pm-1:40pm** **The CEO Champions: Leaders of Successful European Biotech and Life Sciences Companies**
- Chair: Amber Tong, Senior Editor, Endpoints News
- Renée Aguiar-Lucander, Chief Executive Officer, Calliditas Therapeutics
 - John Dawson, Chief Executive Officer, Oxford Biomedica
 - Lisa Anson, Chief Executive Officer, Redx Pharma
- 1:45pm-2:15pm** **Fireside Chat**
- Chair: Mike Ward, Global Head of Thought Leadership, Clarivate
- Francesco de Rubertis, Co-Founder & Partner, Medicxi
- 2:15pm-2:45pm** *Virtual 'Tea break' and Networking*
- 2:45pm-3:45pm** **Public Market Investor Panel: Investing in Today and Tomorrow's Innovative Companies**
- Chair: Hannah Kuchler, Global Pharmaceuticals Correspondent, Financial Times
- Ulrica Slåne Bjerke, CIO and Co-Founder of Global Health Care Fund Arctic Aurora LifeSciences, Arctic Asset Management
 - Paul Major, Portfolio Manager, Bellevue Asset Management
 - Victoria Darbyshire, Equity Analyst, J.P. Morgan Asset Management
 - Geraldine O'Keeffe, Partner, LSP (Life Science Partners)
- 3:50pm-4:30pm** **Fireside Chat**
- Chair: Daniel Mahony, Co-head of Healthcare, Polar Capital
- Rice Powell, Chief Executive Officer & Chairman, Fresenius Medical Care
- 4:35pm-5:35pm** **VC Investor Panel: Building the Future Champions**
- Chair: Stephen Hansen, Associate Editor, BioCentury
- Roel Bulthuis, Managing Partner, INKEF Capital
 - Søren Møller, Managing Partner, Novo Holdings
 - Otello Stampacchia, Founder, Omega Funds
 - Maina Bhaman, Partner, Sofinnova Partners
- 5:45pm-7:00pm** *Virtual Networking*



International Strategic Healthcare Communications

Experienced and trusted advisors to some of the world's most exciting public and private companies, large and small across pharmaceuticals, medtech, digital health, biotech and healthcare services, as well as investors focused on the sector.

 Optimumcomms.com  [@OptimumComms](https://twitter.com/OptimumComms)  [@optimum-strategic-communications](https://www.linkedin.com/company/optimum-strategic-communications)

Welcome



Mary Clark, Managing Director, Optimum Strategic Communications

Mary Clark has a 25 year successful track record in providing strategic corporate and financial communications to both early- and late-stage life sciences healthcare companies. Mary has run high-profile PR campaigns and has been instrumental in assisting companies with strategic positioning and fundraising rounds from seed and private financings through IPOs, as well as numerous follow-on public financings. She has worked with over 100 healthcare clients across Europe and the US. Mary has built and led healthcare businesses at several international PR & IR agencies. She co-founded Optimum in 2017.

SPEAKERS

This year's event once again hosts another stellar line up of industry speakers, as well as the most influential investors in the healthcare sector, who will be sharing their views and providing insights on the future landscape of the new world.


The CEO Champions: Leaders of Successful European Biotech and Life Sciences Companies

Chair: Amber Tong, Senior Editor, Endpoints News



Amber Tong is Senior Editor at Endpoints News, where she reports on key industry news and in-depth features while keeping an eye on the overall voice and look of the publication. Though she has explored a diverse set of topics since joining the Endpoints team in 2017, she is particularly passionate about biopharma trends in China as a Hong Kong native. Amber holds an anthropology degree from Rice University and has previously written for and edited the Rice Thresher, Houstonia Magazine, Governing Magazine and The Chautauquan Daily. She lives in Hong Kong and is bilingual in Chinese and English.

Renée Aguiar-Lucander, Chief Executive Officer, Calliditas Therapeutics



Renée Aguiar-Lucander joined Calliditas as CEO and soon set out to transform the company, laying out a new strategy, recruiting the team in Europe and US, developing the clinical asset, preparing market access activities, ultimately driving the business forward. Renée took Calliditas from its initial listing on the Swedish stock exchange in 2018 – in what was one of the largest European IPOs that year – to a successful listing on US NASDAQ in June 2020 raising \$90 million.

In 2019, Renée signed a multimillion dollar deal with Everest Medicines, expanding the reach of its main product to the Asian market and led negotiations with Regulatory Agencies in the US and Europe which saw the company's main asset allowed to be used in additional niche indications in the liver. Before joining Calliditas, Renée was a Partner and COO of Omega Fund Management, an international venture capital company focused on investments within the life science sector. Before that, she served as a Partner in the venture capital group 3i Group plc in London, where she managed the publicly quoted assets and was co-head of the global healthcare and technology portfolio. Prior to this, Renée was the European Group Head and Managing Director at a global investment bank and has more than 12 years' experience in corporate finance. She has more than 20 years of US and European private and public direct investment, deal structuring & execution. She also has extensive Board experience across private and public enterprises on both sides of the Atlantic.



John Dawson, Chief Executive Officer, Oxford Biomedica

John Dawson joined Oxford Biomedica's Board as Non-Executive Director in August 2008 and was appointed Chief Executive Officer in October 2008. Previously, he held senior management positions in the European operations of Cephalon Inc., including Chief Financial Officer and Head of Business Development Europe. While at Cephalon he led many deals building the European business to over 1,000 people, and to a turnover of several hundred million US dollars and in 2005 led the US\$360 million acquisition of Zeneus by Cephalon. Prior to this time at Cephalon he was Director of Finance and Administration of Serono Laboratories (UK) Limited.



Lisa Anson, Chief Executive Officer, Redx Pharma

Lisa Anson joined as Chief Executive Officer of Redx Pharma on 1 June 2018. Lisa had previously been President of AstraZeneca UK since 2012 and has significant leadership experience in pharmaceuticals. Over a 20 year career at AstraZeneca plc, Lisa has held a number of senior management roles in both the US and the UK including Global Vice President, Oncology and as Vice President of emerging brands where she worked closely with the Research and Development teams.

Lisa holds an MBA (awarded with distinction) from INSEAD, France and a First Class honours degree in Natural Sciences from Cambridge University in the UK. Upon graduating she joined KPMG in London as a management consultant and then moved to California where she worked for Salick Health Care (now Aptium), a cancer disease management company, prior to joining Zeneca Pharmaceuticals (USA) in 1998 as a business development manager.

Lisa has also been President of the Association of the British Pharmaceutical Industry (ABPI), a position from which she stepped down in 2018. She was a Board member of the ABPI from 2012 during which time she has chaired a number of UK industry committee's and worked closely with the UK Government. In 2018 she was elected to the Board of the Bio Industry Association (BIA).

Fireside Chat



Mike Ward, Head of Thought Leadership, Clarivate

Mike Ward serves as Global Head of Thought Leadership at Clarivate. As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. He has held editorial and content leadership roles at various publications and organizations across the industry. In 2010, he was named European Mediscience Commentator of the Year and has been on the short list on other occasions in the past decade. In 2018, he was fourth on Labiotech EU's list of "Biotech Leaders You Should Know in the UK's Golden Triangle."



Francesco de Rubertis, Co-Founder & Partner, Medicxi

Francesco is a co-founder and Partner at Medicxi. Prior to Medicxi, Francesco was a Partner at Index Ventures for 19 years, having joined the firm in 1997 to launch its life sciences practice. Under his leadership, the asset-centric approach to life sciences investing was conceived and adopted. Francesco currently serves on the boards of a number of portfolio companies, including Rivus Pharmaceuticals and is Chairman of Centessa Pharmaceuticals.

Francesco received a B.A. in Genetics and Microbiology from the University of Pavia (Italy) and a PhD in Molecular Biology from the University of Geneva (Switzerland) after which he became a postdoctoral scientist at the Whitehead Institute at M.I.T. He is a Chartered Financial Analyst and serves on the main board of the University of Geneva (Switzerland).

In November 2017 Francesco was named in the first "Bloomberg 50" as one of the Top 50 entrepreneurs and innovators who helped to define Global Business in 2017.

Public Market Investor Panel: Investing in Today and Tomorrow's Innovative Companies



Chair: Hannah Kuchler, Global Pharmaceuticals Correspondent, Financial Times

Hannah Kuchler is the global pharmaceuticals correspondent for the Financial Times. She has worked for the FT for twelve years in the US, Europe and Asia, including reporting on the Covid-19 pandemic and the race for vaccines, and helping create an Emmy-nominated documentary about the opioid crisis. Before covering the pharma industry, she was based in Silicon Valley for five years, writing about technology, including social media and cyber security.



Ulrica Slåne Bjerke, CIO and Co-Founder of Global Health Care Fund Arctic Aurora LifeSciences, Arctic Asset Management

Ulrica Slåne Bjerke, MBAsc, CEFA is CIO and co-founder of the global health care fund Arctic Aurora LifeScience at Arctic Asset Management in Stockholm. Ulrica is heading up a team of four investments professionals managing the funds out of Stockholm in Sweden. Recently, a second fund Arctic Aurora Biotech, purely focused on biotech, was launched. Before starting the healthcare fund back in 2016, Ulrica held a position as responsible for life science investments at the Third National Swedish Pension Fund, AP3. Ulrica has more than thirty years of experience from analyzing and investing in public life science companies.

Arctic Aurora LifeScience has approximately 250 MUSD under management and has shown a strong performance since start, with the USD class up 83% since inception. Due to its focus on break through innovations aimed towards unmet medical needs, the fund has a large exposure to biotech. The team has a strong track record in stock selection within biotech, which formed the basis for the start of the newly launched pure biotech fund, Arctic Aurora Biotech Select.



Paul Major, Portfolio Manager, Bellevue Asset Management

Paul Major is a Portfolio Manager at Bellevue Asset Management, which manages the BB Healthcare Trust. He has 18 years of experience in the healthcare sector on the sell-side and was top-rated by a number of institutional investment clients. He was one of the first research partners at Redburn, Europe's leading independent research firm. His work there included bespoke projects on healthcare portfolio construction for several institutions. Paul was previously an analyst and corporate financier at UBS Warburg and studied biochemistry.



Victoria Darbyshire, Equity Analyst, J.P. Morgan Asset Management

Victoria Darbyshire joined J.P. Morgan Asset Management in the European Research team covering the healthcare sector more than ten years ago. She also contributes to the J.P. Morgan Global Healthcare Fund. She became a CFA Charterholder in 2009 and has a BSc in Chemistry from Durham University.



Geraldine O'Keeffe, Partner, LSP (Life Science Partners)

Geraldine O'Keeffe joined LSP in 2008. She became a Partner of the firm in 2010. Geraldine's prime focus and responsibility within LSP is to invest in listed securities. Prior to joining LSP, she held the position of Senior Healthcare Analyst at Fortis Investment Banking. In that position, she researched a wide range of innovative life sciences companies, both in Europe and the US.

Geraldine brings strong analytical and investment skills to the LSP team. Before joining the financial community, she worked within the life sciences industry for a number of years, gaining first-hand product development experience in a commercial setting. Prior to working in the industry, she lectured in Biomedical Sciences for several years at the Dublin Institute of Technology. Geraldine has a very strong scientific background, including a Bachelor's degree in Biochemistry and Microbiology from University College Cork and a Master's degree in Biotechnology from University College Galway. She also conducted post-graduate research, inter alia at the prestigious Max Planck Institute for Biophysical Chemistry in Göttingen, Germany. In addition, Geraldine is also a graduate of The Dublin School of Business. Geraldine lives in Amsterdam with her husband and two children.

Fireside Chat



Daniel Mahony, Co-head of Healthcare, Polar Capital

Daniel Mahony is Co-Head of the Healthcare team at Polar Capital. He studied biochemistry at the University of Oxford and received his Ph.D. from the University of Cambridge. Daniel moved to California to work as a research scientist at Schering Plough Corporation (now Merck & Co.) in 1995 and made the transition into financial services in 1998, working for ING Barings in New York and Morgan Stanley in London as head of the European healthcare research team. In 2007, he set up Polar Capital's healthcare team. He has over 29 years of experience within global healthcare covering sectors including biotechnology, medical technology and healthcare services.



Rice Powell, Chief Executive Officer and Chairman, Fresenius Medical Care

Rice Powell is Chief Executive Officer and Chairman of the Management Board effective January 1, 2013. Prior to that, he was Vice Chairman of the Management Board and Member of the Management Board responsible for the region North America from 2010 to 2012. He joined Fresenius Medical Care in 1997 and was appointed to the company's Management Board and Co-CEO of Fresenius Medical Care North America in January 2004. He has over 36 years of experience in the health care industry. From 1978 to 1996, he held various positions, among others at Baxter International Inc. and Biogen Inc. in the U.S.

VC Investor Panel: Building the Future Champions



Chair: Stephen Hansen, Associate Editor, BioCentury

Stephen Hansen is BioCentury's Associate Editor in the U.K., where he serves as one of the company's primary points of contact with European companies and investors. Stephen has covered clinical development, corporate strategy and finance in Europe, the U.S. and China for BioCentury for over a decade and is a frequent contributor to BioCentury's quarterly Financial Markets Preview and annual Buyside View and European Finance reports. He holds B.A.s in Biology and History from Bethel University and an M.Phil. in History from Oxford University.



Roel Bulthuis, Managing Partner, INKEF Capital

Roel Bulthuis is a Managing Partner and head of the Healthcare investment team at INKEF. Roel combines more than 15 years of experience across venture capital, pharma business development and investment banking. Prior to joining INKEF he served as an SVP and Managing Director of M-Ventures which he created and developed into a leading CVC fund. Prior to that, he served in senior positions in global business development at Merck Serono and in the investment banking team at Fortis Bank. Roel is a Kauffman Fellow and passionate about continuously challenging the status quo. Roel holds a Msc. in Biopharmaceutical Sciences from Leiden University and an MBA in Finance from the Helsinki School of Economics.



Søren Møller, Managing Partner, Novo Holdings

Søren Møller joined Novo Holdings A/S in 2011 as Managing Investment Director of Novo Seeds. Søren obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark. In addition, Søren has academic training as postdoctoral fellow at Stanford University School of Medicine.

Prior to joining Novo Seeds, Søren served as global manager of Genomics at Novozymes. Before Novozymes, Søren was CSO and Vice President of R&D at Exiqon A/S. During Søren's tenure, Exiqon completed an IPO and the company was acquired by Qiagen in 2016. Previously, Søren worked in cancer drug development as head of Lead Identification at BiImage and as research scientist at Novo Nordisk.


Søren serves on the Board of Directors of EpiTherapeutics (sold to Gilead), AMRA, Biosyntia, Reaplix and Northsea Therapeutics. Since 2008, Søren has been board member of Danish Biotech (the Association of Biotechnology Industries in Denmark) and DVCA (Danish Venture Capital Association).



Otello Stampacchia, Founder, Omega Funds

Otello Stampacchia founded Omega Funds in 2004 and leads the firm's investor relations and strategic initiatives. He is a member of the firm's investment committee and is also heavily involved in a number of Omega's therapeutic areas of interest, particularly in oncology, rare diseases and inflammatory disorders.

Previously, Otello was in charge of life sciences direct investments and diligence for healthcare venture fund of fund investments at AlplInvest Partners, one of the largest private equity asset managers worldwide. Before AlplInvest, he was the portfolio manager of the Lombard Odier Immunology Fund, a \$3 billion listed investment vehicle in Geneva, Switzerland, investing in public and private healthcare companies worldwide. Previously, Otello was a member of the HealthCare corporate finance and M&A team at Goldman Sachs (London and New York offices). Before Goldman, he helped co-found the healthcare investment activities at Index Securities (now Index Ventures). Otello has a PhD in Molecular Biology from the University of Geneva, holds a European Doctorate in Biotechnology from the EU, and obtained an MSc in Genetics from the University of Pavia.



Maina Bhaman, Partner, Sofinnova Partners

Maina Bhaman is a partner at Sofinnova Partners. She joined the firm in 2018 and has a long track record as a successful healthcare investor.

Prior to joining Sofinnova Partners, Maina was Director of Healthcare Investment at Touchstone Innovations (formerly Imperial Innovations) in London, UK, where she led and co-led investments in the UK.

Previously, she worked in the R&D teams of several UK and US biotech companies, including Celltech, Oxford Glyco Sciences, Chimeric Therapies and GeneMedicine.

Maina holds a B.S. from the University of Texas at Austin and an MBA from the Imperial Business School. Maina's current investments include Sitryx Therapeutics, Cincor and Enyo Pharma.

INTERNATIONAL STRATEGIC, LIFE SCIENCES HEALTHCARE COMMUNICATIONS



Strategic, proactive & effective corporate communications and investor relations in Europe and US - helping clients communicate a compelling story to important stakeholders



Healthcare and life sciences specialists who have worked with over 300 companies



Successful track record helping companies raise their profile in the international top tier media ahead of fund raisings and to attract significant investment from European and US investors



Unrivalled network of contacts in the investment community and media – across Europe and US



In-depth research and analysis, combined with knowledge of the global healthcare industry, enabling us to provide clients with the best-informed and most creative advice on building a compelling investment story



Team of experienced, senior and leading healthcare specialist advisors in the sector

Effectively communicating a company's strategy, growth ambitions, and the reasons to "invest now" are critical for management teams as they seek to build investor confidence and support. Based on our unique experience and insight, Optimum provides each client with a bespoke, integrated communications service.

- ✓ Access to Investors
- ✓ Sellside Analyst Relations
- ✓ World Class Media Relations
- ✓ Profile Raising
- ✓ Corporate Communications

- ✓ Private Financing
- ✓ IPOs
- ✓ M&A
- ✓ Optimum Perception Studies
- ✓ Developing Content

- ✓ Crisis Communications
- ✓ Digital & Social Media
- ✓ Presentation & Media Coaching
- ✓ Conference Support

OPTIMUM
STRATEGIC COMMUNICATIONS

Amsterdam



London



Los Angeles



New York



Stockholm



Zurich



Optimumcomms.com



[@OptimumComms](https://twitter.com/OptimumComms)



[@optimum-strategic-communications](https://www.linkedin.com/company/optimum-strategic-communications)

SELECT CLIENTS

Worked with over
300 healthcare
companies

UK

Amber Therapeutics
Artios Pharma
Arix Bioscience
Biocomposites
Bionical Solutions
ConserV
Curve Therapeutics
Dark Blue Therapeutics
Destiny Pharma
Edinburgh Molecular Imaging
F2G
Flexipharm
Futura Medical
Invizius
Leucid Bio
Macrophage Pharma
Masters Speciality Pharma
Medicxi
NeoPhore
OriBiotech
Sixth Element Capital
STORM Therapeutics
Synox
Theragnostics
ValiRx
Verona Pharma

BELGIUM

Apitope
Enzyre
eTheRNA
ExeVir Bio
Fund+
Galapagos

DENMARK

Acesion Pharma
Adcendo
Antag Therapeutics
BioInnovation Institute
Eir Ventures
Hemab
Muna Therapeutics
Novo Holdings
Reaplix
Synklino

FINLAND

DelSiTech
Forendo Pharma
Rappta Therapeutics

FRANCE

Depixus
Micropep Technologies

GERMANY

AMSilk
Bayer
Evotec
Fresenius Medical Care
Heidelberg Pharma
vasopharm

HUNGARY

Turbine Ai

ISRAEL

Teva Pharmaceuticals

LUXEMBOURG

Vesalius BioCapital

THE NETHERLANDS

Gadeta
ISA Pharmaceuticals
INKEF Capital
Kiadis Pharma
LSP
M Ventures
Salvia BioElectronics
Synaffix

NORWAY

EXACT Therapeutics

SWEDEN

Ascelia Pharma
Calliditas Therapeutics
HealthCap
Vicore Pharma

SWITZERLAND

Asceneuron
BaseLaunch
Chord Therapeutics
FoRx Therapeutics
NBE Therapeutics
Synendos
Versameb

SPAIN

Inbiomotion
Medlumics
Neuraxpharm
Ona Therapeutics

USA

ImaginAb
Centessa Pharmaceuticals

FINANCING / M&A



Launched with \$250m Series A Financing + \$330m IPO Among Largest on NASDAQ This Year



Raises €37m in Series A Financing



Led \$152m Series B Financing in Pyxis Oncology



Led \$200m Series A in Asia-based, Esco Lifesciences Group and \$118m Series C Investment in Genomatica



Raised \$55m Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders



Raised €51m in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers



Launched with \$73m Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases



Acquired by Sanofi for €308m



Acquired by Boehringer Ingelheim for €1.18bn



Raised €8.5m in oversubscribed Series A Financing to Develop Innovative Small Peptide Solutions for Agriculture



Raised Series A Financing to Develop Anti-inflammatory Treatment for Haemodialysis



Raised US\$50m Series A Financing



Raised \$153m Series C Financing Led by Omega Funds and TCG X



Raised €26m to Develop Immunotherapeutics Against Cancer and Viral Infections



Raises CHF 24m in Series A Financing



Acquired by Worg Pharmaceuticals



LICENSING / MILESTONES



Received Fast Track Designation for Lead Product ISA101b



Artios Collaboration with Novartis to Create Next Generation DDR Cancer Therapies



Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not On Prophylaxis



Collaboration with Labatec Pharma to Commercialise MED3000 in the Gulf and Middle East Region



BioInnovation Institute Launched Venture Lab Program of Innovative Early-Stage Companies



First Patient Dosed with Gadeta's Gamma Delta TCR Cell Therapy



New Approval For STIMULAN® to Treat Bacterial Infection



Received FDA Fast Track Designation for Setanaxib in PBC



Phase 1b/2 Clinical Study Evaluating XVR011 as Antiviral Treatment of Patients Hospitalised for COVID-19



Exclusive Licensing and Collaboration Agreement with Visus Therapeutics for the Development of Long-Acting Therapies in Ophthalmology



Strategic Collaboration with Quantoom Biosciences for the Development of a Novel RNA Production System



Positive Update on Microbiome Therapeutic NTCD-M3



Novo Seeds Launched Tribune Therapeutics to Develop Novel Medicines Targeting a Wide Range of Fibrotic Diseases



Partnered with STADA to Register and Commercialize Specialty Therapy for IgA Nephropathy in Europe



Entered Strategic Partnership with Takeda to Accelerate Pioneering Diagnostic Technology Platform for Hemophilia Patients



Announced Multiple Abstracts Related to its K-NK-Cell Therapy



Funds Worlds First Research Centre to Find Solutions to Reduce CO2 in the Atmosphere and Convert it Into Valuable Raw Materials



China Medical System Joins BaseLaunch as Latest Partner



Receives Approval from EU Notified Body for MED3000



\$219m Strategic Collaboration with Nuance Pharma to Develop & Commercialize Ensifentrine in Greater China

AWARDS 2021



Optimum Strategic Communications ranked in MergerMarket's M&A PR advisor league tables for deals worked on in 1H2020



OPTIMUM CONNECTIONS

Optimum Connections, our monthly newsletter contains insights from across the healthcare industry. Click the thumbnails below to watch/read insightful content from our Optimum network...

If you would like to join our mailing list please contact us on contact@optimumcomms.com

Doing the *Right* Right Thing,
and Doing it Better...

**A Life Sciences
Primer on ESG**

NOMURA



Alex Rowe
Sustainable Equities
Portfolio Manager,
Nomura

Daniela Dorelova
ESG Investment
Specialist,
Nomura

Read now

Investor Q&A Series

Roel Bulthuis
Managing Partner
inkef capital




OPTIMUM
STRATEGIC COMMUNICATIONS

**TOP TAKEAWAYS
KEYNOTE SPEAKER**

Kate Bingham
PM asked her to vaccinate the population
The triumph of science & collaboration
Time was of the essence

CONGRATULATIONS
ON YOUR
DAMEHOOD KATE!



Dame Kate Bingham
Managing Partner
SV Health Investors

one nucleus

**ANGLO | LIFE SCIENCE
NORDIC | CONFERENCE**

ORGANISED BY
OPTIMUM
STRATEGIC COMMUNICATIONS

New Medicines in a Brave New World

A Spotlight On mRNA

5-6 July 2021 | On Helix Digital

on helix

**ThermoFisher
SCIENTIFIC**

versameb

eTheRNA
immunotherapies

Lilly

OPTIMUM
STRATEGIC COMMUNICATIONS

one nucleus

Where do professional investors think
the long term returns are going to be?

**BRITISH | CHAMBER OF
SWISS | COMMERCE**



CHAIR: MARY CLARK
Managing Director
Optimum Strategic Communications

GAVIN MACGREGOR
Portfolio Manager
HBM Partners

STEFAN BLUM
Fund Manager
Belvue Asset Management AG

DR TERENCE MCMANUS
Portfolio Manager
J. Safra Sarasin

TAKEAWAYS FROM THE INVESTMENT IN HEALTHCARE SESSION
@ NEW FRONTIERS IN HEALTHCARE CONFERENCE 25TH - 27TH MAY 2021

BioWednesday Webinar:
Concussions and sports-
related injuries



one nucleus
The Business Network for Life Sciences

OXEIA
BIOINFORMEDICS

**CHARLES
STANLEY**

DRG
Part of Clarivate

Agility

Lilly

OPTIMUM
STRATEGIC COMMUNICATIONS

**READ OPTIMUM'S
TOP TAKEAWAYS**



International Women's Day

Optimum Strategic Communications celebrated International Women's Day with a mighty social media campaign!

We asked 50 brilliant women in biotech/healthcare what is their 'one main positive to come out of the crises?'

Please follow the [link](#) to discover their insights.



Happy International Women's Day 2021

To celebrate, Optimum asked the brilliant women in our sector their **one main positive** that has come from our collective experience of the pandemic.



OPTIMUM
STRATEGIC COMMUNICATIONS



International Women's Day

INDUSTRY PARTNERS

Optimum proudly supports a number of key industry partners



Strengthening Our United Kingdom
of Life Scientists

WOMEN AHEAD
OF THEIR TIME



The Society for Medicines Research



MEET THE OPTIMUM TEAM



Mary Clark



Supriya Mathur



Eva Haas



Hollie Vile



Manel Mateus



Charlotte Hepburne-Scott



Elakiya Rangarajah



Stella Lempidaki



Jonathan Murphy



Abbie Murphy



Monica Clark




Vici Rabbetts



Zoe Bolt



Kathy Vincent



Leti McManus



Bill Douglas



OPTIMUM

STRATEGIC COMMUNICATIONS

Please contact us to see how we can help your strategic communications
mary@optimumcomms.com

Amsterdam



London



Los Angeles



New York



Stockholm



Zurich



Optimumcomms.com



[@OptimumComms](https://twitter.com/OptimumComms)



[@optimum-strategic-communications](https://www.linkedin.com/company/optimum-strategic-communications)